Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
LM-108 by LaNova Medicines for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
LM-108 is under clinical development by LaNova Medicines and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...